{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05861999",
            "orgStudyIdInfo": {
                "id": "BN44621"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-505161-81-00",
                    "type": "REGISTRY",
                    "domain": "EU CT number"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy",
            "officialTitle": "A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy",
            "acronym": "HINALEA 2",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-evaluating-the-effectiveness-and-safety-of-risdiplam-administered-in-pediatric-patients-with-spinal-muscular-atrophy-who-experienced-a-plateau-or-decline-in-function-after-gene-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-30",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-08",
            "studyFirstSubmitQcDate": "2023-05-08",
            "studyFirstPostDateStruct": {
                "date": "2023-05-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-04",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children \\<2 years of age genetically diagnosed with SMA."
        },
        "conditionsModule": {
            "conditions": [
                "Muscular Atrophy, Spinal"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 28,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Risdiplam",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive risdiplam orally once daily for 72 weeks (Treatment Period). The Treatment Period will be followed by a 1-year Treatment Extension Period for a total study duration of 120 weeks (approximately 2.5 years) for each participant enrolled.",
                    "interventionNames": [
                        "Drug: risdiplam"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "risdiplam",
                    "description": "Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.",
                    "armGroupLabels": [
                        "Risdiplam"
                    ],
                    "otherNames": [
                        "RO7034067"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change from Baseline in the Raw Score of Bayley Scales of Infant and Toddler Development - Third Edition (BSID-III) Gross Motor Score at 72 Weeks of Risdiplam Treatment",
                    "timeFrame": "Baseline, Week 72"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants With Adverse Events",
                    "timeFrame": "Up to 120 weeks"
                },
                {
                    "measure": "Percentage of Participants With Serious Adverse Events",
                    "timeFrame": "Up to 120 weeks"
                },
                {
                    "measure": "Percentage of Participants With Treatment Discontinuation Due to Adverse Events",
                    "timeFrame": "Up to 120 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change from Baseline in Bulbar/Swallowing Function Assessment as Measured by the Oral and Swallowing Abilities Tool (OrSAT) at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Change in Swallowing Function Assessment as Measured by the Pediatric Functional Oral Intake Scale (p-FOIS) at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Change from Baseline in the Raw Score of BSID-III Gross Motor Score Over Time Under Risdiplam Treatment",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Percentage of Participants With a Gross Motor Index Between 80-109 as Measured by the Peabody Developmental Motor Scale, Third Edition (PDMS-3) at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Percentage of Participants With a Fine Motor Index Between 80-109 as Measured by the PDMS-3 at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Change in World Health Organization (WHO) Motor Milestone Achievement at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Percentage of Participants With Improvement or No Change in Respiratory Illness as Assessed by Clinical Global Impression of Change (CGI-C)",
                    "timeFrame": "As per respiratory event on Day 10 and Day 20 postevent (up to Week 120)"
                },
                {
                    "measure": "Percentage of Participants Within 3rd Percentile of Normal Range for Weight-to-Age at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Percentage of Participants Within 3rd Percentile of Normal Range for Length/Height-to-Age at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Percentage of Participants Within 3rd Percentile of Normal Range for Weight-to-Length/Height at 72 Weeks of Risdiplam Treatment and Over Time",
                    "timeFrame": "From baseline up to Week 120"
                },
                {
                    "measure": "Number of Respiratory-Related Hospitalizations During the 72-Week Risdiplam Treatment and Over Time",
                    "timeFrame": "Up to 120 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \\<2 years of age at the time of informed consent\n* Confirmed diagnosis of 5q-autosomal recessive SMA\n* Confirmed presence of two SMN2 gene copies\n* Administration of onasemnogene abeparvovec pre-symptomatically or post-symptomatically\n* Has received onasemnogene abeparvovec for SMA no less than 3 months prior to enrollment\n* In the opinion of the investigator, has demonstrated a plateau or decline in function post-gene therapy (with a duration of 6 months or less) documented by 2 individual time points in the functions as follows: swallowing AND one additional function/ability (respiratory, motor function, other) per appropriate expectation.\n\nExclusion Criteria:\n\n* Treatment with investigational therapy prior to initiation of study treatment\n* Any unresolved standard-of-care laboratory abnormalities per the onasemnogene abeparvovec prescribing information\n* Concomitant or previous administration of a SMN2-targeting antisense oligonucleotide or SMN2 splicing modifier either in a clinical study or as part of medical care\n* Requiring invasive ventilation or tracheostomy\n* Presence of feeding tube and an OrSAT score of 0\n* Hospitalization for pulmonary event within the last 2 months, or any planned hospitalization at the time of screening\n* Any major illness requiring hospitalization within 1 month before the screening examination or any febrile illness within 1 week prior to screening and up to first dose administration.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "3 Months",
            "maximumAge": "24 Months",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: BN44621 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Arkansas for Medical Sciences",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "Valley Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Madera",
                    "state": "California",
                    "zip": "93636",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.96134,
                        "lon": -120.06072
                    }
                },
                {
                    "facility": "Instytut Pomnik Centrum Zdrowia Dziecka; Klinika Neurologii i Epileptologii",
                    "status": "RECRUITING",
                    "city": "Warszawa",
                    "zip": "04-730",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.22977,
                        "lon": 21.01178
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "This clinical trial evaluates treatment of a rare genetic disease in a small cohort of participants. No data is planned to be shared in order to protect and maintain participant privacy/confidentiality."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009133",
                    "term": "Muscular Atrophy"
                },
                {
                    "id": "D000009134",
                    "term": "Muscular Atrophy, Spinal"
                },
                {
                    "id": "D000001284",
                    "term": "Atrophy"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020763",
                    "term": "Pathological Conditions, Anatomical"
                },
                {
                    "id": "D000020879",
                    "term": "Neuromuscular Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000013118",
                    "term": "Spinal Cord Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000016472",
                    "term": "Motor Neuron Disease"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4589",
                    "name": "Atrophy",
                    "asFound": "Atrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12090",
                    "name": "Muscular Atrophy",
                    "asFound": "Muscular Atrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12091",
                    "name": "Muscular Atrophy, Spinal",
                    "asFound": "Muscular Atrophy, Spinal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22519",
                    "name": "Pathological Conditions, Anatomical",
                    "relevance": "LOW"
                },
                {
                    "id": "M22619",
                    "name": "Neuromuscular Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M15915",
                    "name": "Spinal Cord Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18879",
                    "name": "Motor Neuron Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M4024",
                    "name": "Amyotrophic Lateral Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5342",
                    "name": "Spinal Muscular Atrophy",
                    "asFound": "Spinal Muscular Atrophy",
                    "relevance": "HIGH"
                },
                {
                    "id": "T349",
                    "name": "Amyotrophic Lateral Sclerosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629884",
                    "term": "Risdiplam"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009465",
                    "term": "Neuromuscular Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M264314",
                    "name": "Risdiplam",
                    "asFound": "Streptococcus salivarius",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}